Published papers
Academic conference presentation
    （Last updated : 2026-03-06 14:04:15）
  NEMOTO Yuuki
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine  Department of Urology
   Position   Research Associate
■ Published papers
1. Original article　 Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
2. Case report　 Safety management of kidneytransplantation in patients with Behçet’s disease: A case report with literature review 2026/02/10
3. Original article　 Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
4. Original article　 Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
5. Original article　 Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
Display all(40)
■ Academic conference presentation
1. Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （ポスター掲示，一般） 2025/09/26
2. Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. （ポスター掲示，一般） 2025/04/29
3. Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （ポスター掲示，一般） 2025/04/28
4. Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （ポスター掲示，一般） 2025/04/28
5. Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （ポスター掲示，一般） 2024/05/03
Display all(20)